But the timeline for a US green light is less clear, and the group has a cash crisis.

Investors will hope for a JP Morgan buying spree, while readouts could come from Kura, Allogene and MacroGenics.

The group reports more data today, while its pivotal Ares trial, in acute graft-versus-host disease, is set to read out in the fourth quarter.